Last reviewed · How we verify
Mirikizumab - SC
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut.
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut. Used for Ulcerative colitis, Crohn's disease.
At a glance
| Generic name | Mirikizumab - SC |
|---|---|
| Also known as | LY3074828 |
| Sponsor | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives |
| Drug class | IL-23 inhibitor monoclonal antibody |
| Target | IL-23 p19 subunit |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
IL-23 is a key cytokine driving Th17 cell differentiation and intestinal inflammation. By blocking the p19 subunit of IL-23, mirikizumab prevents IL-23-mediated immune activation while preserving IL-12 signaling, which is important for antimicrobial immunity. This selective IL-23 inhibition reduces pathogenic T cell responses in inflammatory bowel disease.
Approved indications
- Ulcerative colitis
- Crohn's disease
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Injection site reactions
Key clinical trials
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (PHASE3)
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) (PHASE3)
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (PHASE3)
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (PHASE3)
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease (PHASE2)
- A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease (PHASE2)
- A Study of Mirikizumab Solution (LY3074828) in Healthy Participants (PHASE1)
- A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: